Prasterone (Intrarosa): Complete Guide to Vaginal DHEA for Menopause

Prasterone (brand name Intrarosa) is an FDA-approved intravaginal insert containing 6.5 mg of dehydroepiandrosterone (DHEA), placed nightly to treat moderate-to-severe painful sex (dyspareunia) caused by vulvovaginal atrophy in postmenopausal women. It works locally, inside vaginal tissue, rather than by raising hormone levels throughout the body. This distinguishes it from systemic estradiol products such as patches, pills, gels, and sprays, which treat hot flashes, night sweats, and bone loss but are not required to treat vaginal-only symptoms. Prasterone is not a substitute for systemic hormone therapy when a woman also needs relief from vasomotor symptoms or bone protection.

What is genitourinary syndrome of menopause, and where does prasterone fit?

Genitourinary syndrome of menopause (GSM) is the umbrella term for the vaginal, vulvar, and urinary changes that follow estrogen decline after menopause: dryness, thinning tissue, painful sex, and urinary symptoms such as urgency or recurrent infection. A 2026 review of the urinary manifestations of GSM describes the pathophysiology and management landscape for this condition, including the range of local and systemic treatment options clinicians consider (Urinary manifestations of genitourinary syndrome of menopause, 2026, see reference below). Prevalence estimates for GSM vary considerably across studies and populations; readers should treat any single percentage figure as an estimate rather than a fixed rate, and clinicians should verify current prevalence data before citing a specific number to a patient.

Prasterone exists because a meaningful share of women with GSM either cannot use systemic estrogen or prefer not to. It offers a way to treat vaginal atrophy and dyspareunia with minimal intended systemic hormone exposure. It does not address hot flashes, does not protect bone density at the spine or hip, and does not treat mood or sleep symptoms tied to systemic estrogen decline. Women who need those benefits require a systemic estrogen formulation in addition to, or instead of, Intrarosa.

How prasterone works: local hormone conversion, not systemic dosing

The concept behind prasterone is called intracrinology. Vaginal epithelial cells contain the enzymes needed to convert DHEA into androgens and estrogens on-site. When prasterone is absorbed by these cells, local hormone concentrations rise enough to stimulate androgen receptors (which support vaginal wall thickness) and estrogen receptors (which support lubrication and elasticity), while the hormone produced is largely metabolized before it reaches the bloodstream in meaningful quantities.

This is the basis of prasterone's safety profile: it is designed so that serum estradiol and testosterone levels remain close to a woman's normal postmenopausal baseline rather than rising toward premenopausal or therapeutic systemic levels. Readers and prescribers should confirm the specific pharmacokinetic numbers (serum estradiol ranges, comparison to vaginal estradiol tablets) against the current FDA prescribing information rather than relying on any single secondary source, since exact figures can be cited inconsistently across review articles.

What the clinical trial evidence shows, and where the numbers need verification

Prasterone's approval rested on a Phase 3 clinical trial program in postmenopausal women with moderate-to-severe dyspareunia as their most bothersome GSM symptom. Published trial reports describe improvements versus placebo across several measures: the proportion of superficial versus parabasal vaginal cells (a marker of tissue maturation), vaginal pH, and patient-reported dyspareunia severity, generally assessed at 12 weeks.

This article previously cited specific percentage-point changes and p-values attributed to a named trial. Those exact figures could not be verified against a confirmed primary source in this review and are not reproduced here. A qualified reviewer should pull the original trial publication or the current FDA label before any specific numeric claim (percentage change, p-value, adverse event rate) is published to readers. What can be stated with more confidence, based on the consistent direction of findings across the published literature, is that prasterone showed a statistically significant benefit over placebo on objective vaginal tissue measures and on patient-reported dyspareunia in the trials supporting its approval. Vaginal discharge was the most commonly reported adverse event in the trial program; no endometrial hyperplasia or malignancy was reported in prasterone-treated participants, though biopsy substudies were limited in size and duration.

The NAMS 2023 Menopause Hormone Therapy Position Statement lists prasterone, alongside low-dose vaginal estrogen and ospemifene, as an option for women with GSM who want a localized, non-systemic therapy. Readers should consult the position statement directly for the exact wording of its recommendation rather than relying on a quoted excerpt, since the precise phrasing in any secondary summary (including earlier versions of this page) requires direct verification against the source document.

Systemic estradiol options: patch, pill, gel, and spray

Many women need systemic symptom control in addition to, or instead of, local GSM treatment. The main estradiol delivery routes differ meaningfully in pharmacokinetics and risk profile.

Oral estradiol

Oral estradiol is taken daily and passes through the liver before reaching general circulation (first-pass metabolism), which raises sex hormone-binding globulin and can affect triglycerides and clotting factors more than transdermal routes do. Observational and case-control data in the literature have associated oral, but not transdermal, estrogen with a higher risk of venous thromboembolism (VTE); the exact magnitude of that difference varies by study and should be confirmed against a specific, verified source before being quoted as a fixed multiple. Oral estradiol is typically the lowest-cost systemic option and suits women with no personal VTE history who are comfortable with daily pill-taking.

Transdermal estradiol patch

Patches deliver estradiol continuously through the skin, bypassing first-pass liver metabolism, and are changed once or twice weekly depending on the product. Because the estradiol-to-estrone ratio stays closer to premenopausal physiology, the VTE signal associated with oral estrogen has generally not been replicated with patches in the literature, though individual risk still depends on a woman's personal and family clotting history. Skin irritation and adhesion failure are common practical complaints.

Estradiol gel

Unit-dose estradiol gels (for example, Divigel) are applied once daily, typically to the thigh, and also avoid first-pass hepatic metabolism. Skin-to-skin transfer to a partner or child is a real concern until the site has dried and been covered; patients should be counseled on this explicitly. Trial data supporting FDA approval of gel products showed reduction in moderate-to-severe hot flashes versus placebo over roughly 12 weeks; readers should check the current FDA label for the approved dose range and effect size rather than relying on a specific percentage repeated from a secondary source.

Estradiol transdermal spray

Metered-dose transdermal sprays (for example, Evamist) are applied to the forearm and dry quickly, with dosing usually starting at one spray daily and titrated based on symptom response. As with gel, transfer risk to others exists until the site is dry, and specific trial effect sizes should be confirmed against the current label before being cited precisely.

Choosing between prasterone and systemic estradiol

The decision is often not either/or. This framework, organized around the actual clinical questions that change management, is intended to structure a conversation with a prescriber rather than to replace one.

1. What is the primary symptom driving treatment? If the only or most bothersome symptom is vaginal dryness or pain with sex, local-only therapy (prasterone or low-dose vaginal estradiol) may be sufficient. If hot flashes, night sweats, sleep disruption, or bone density concerns are present, systemic estradiol is generally needed regardless of what local therapy is chosen.

2. Is there a personal or family history of blood clots? A history of DVT, PE, or a known clotting disorder shifts systemic estrogen choice toward transdermal delivery (patch, gel, or spray) rather than oral, based on the general first-pass-metabolism difference described above. Prasterone is not intended to change this calculation because it is not designed to raise systemic hormone levels meaningfully.

3. Does the uterus need protection? Women with an intact uterus who use systemic estrogen require a progestogen to protect the endometrium; the regimen and dose should be set by the prescriber. Because prasterone is not intended to produce significant systemic estrogen exposure, prasterone alone does not require added progestogen, according to the endometrial safety data reported in its trial program.

4. What history affects candidacy for any estrogen-containing product? A history of estrogen receptor-positive breast cancer, active or recent VTE, undiagnosed vaginal bleeding, or known or suspected pregnancy are situations that require individualized discussion with a prescriber (and, for breast cancer history, likely the treating oncologist) before starting prasterone or any estrogen product.

5. What does daily life realistically support? A twice-weekly patch suits someone who dislikes daily routines. A daily gel, spray, or pill suits someone comfortable with a consistent ritual. A nightly vaginal insert is discreet but requires comfort with vaginal self-administration.

6. When should the plan be reassessed? Most trial programs referenced here assessed outcomes around 12 weeks. A reasonable default is to give a chosen regimen at least that long before concluding it has failed, then reassess with the prescriber and adjust dose or route as needed.

Safety profile and contraindications

Prasterone's labeled contraindication is undiagnosed abnormal genital bleeding. Women with a history of estrogen receptor-positive breast cancer should discuss prasterone with their oncologist before starting, because although systemic exposure is intended to be minimal, local vaginal tissue does generate estradiol through intracrinology, and long-term outcome data in breast cancer survivors are limited. Vaginal discharge and mild application discomfort are the most frequently reported side effects in the trial program; a mild cytologic shift on Pap testing can reflect the expected tissue maturation effect of treatment rather than a new abnormality, but any abnormal Pap result still needs standard clinical follow-up rather than being dismissed as expected.

Anyone experiencing new or unexplained vaginal bleeding, pelvic pain, or signs of infection while using prasterone should be evaluated promptly rather than assuming the symptom is treatment-related.

Progestogen: when it is needed, and when it is not

Systemic estradiol, regardless of delivery route, stimulates the endometrium in women who still have a uterus. Without an opposing progestogen, unopposed estrogen exposure raises the risk of endometrial hyperplasia and, over time, endometrial cancer. Older randomized data established this risk clearly enough that unopposed systemic estrogen in a woman with a uterus is considered outside current guideline-supported practice; readers should look to a current, verified primary source for the exact incidence figures rather than a percentage carried over from an older secondary summary.

Prasterone's trial program did not identify endometrial hyperplasia in treated participants, consistent with its design to avoid clinically significant systemic estrogen exposure. This is why a woman using only Intrarosa, with no systemic estrogen, is not generally prescribed a progestogen. Women using any systemic estradiol product (patch, pill, gel, or spray) who have a uterus need a progestogen regimen set by their prescriber; micronized progesterone is one commonly used option, but the specific dose and schedule should come from the treating clinician rather than a general guide.

Using prasterone in practice

The insert is placed vaginally each night at bedtime using the supplied single-use applicator. No refrigeration is required. Some women notice waxy residue from the insert base the following morning; this reflects the delivery vehicle and is not itself a sign the treatment is failing or working. There is no dose titration; the approved dose is one 6.5 mg insert nightly. If severe atrophy makes vaginal insertion uncomfortable at the start, a prescriber may recommend a short conditioning course with another vaginal product first.

A reasonable trial period, consistent with the timeline used in the supporting trials, is around 12 weeks before deciding the treatment has not worked, though some women notice subjective improvement in comfort sooner.

Combining prasterone with systemic HRT

Women already on systemic estradiol who still have persistent vaginal dryness or dyspareunia can generally add prasterone without materially increasing systemic estrogen exposure, since prasterone is not designed to add meaningfully to serum hormone levels. This combination, systemic estradiol for vasomotor symptoms plus prasterone for residual vaginal symptoms, is consistent with the general principle in the NAMS 2023 statement that local vaginal therapy can be added when vaginal symptoms are not fully resolved by systemic treatment alone.

Whether to start with local therapy alone, systemic therapy alone, or both together depends on which symptoms are present and how bothersome they are, along with a woman's cardiovascular history, uterine status, and personal preference. This decision belongs with a prescriber who can review the individual's full history; it is not a decision this guide can make for a specific reader.

Evidence boundary: what is established, what is not

Established: Prasterone is FDA-approved for moderate-to-severe dyspareunia due to vulvovaginal atrophy of menopause. Its trial program showed statistically significant improvement over placebo on vaginal cytology, pH, and patient-reported dyspareunia. It is designed not to require added progestogen because it is not intended to produce clinically significant systemic estrogen exposure. Systemic estradiol delivered orally undergoes first-pass liver metabolism in a way that transdermal routes do not, and this distinction is well established in the pharmacology literature.

Plausible but requiring verification before precise quoting: The exact magnitude of VTE risk difference between oral and transdermal estrogen, the specific percentage-point trial results for prasterone and for Divigel/Evamist, and the exact incidence of endometrial hyperplasia with unopposed estrogen all appear in the literature but were not verified against a confirmed primary source for this draft and should not be repeated as precise figures without that verification.

Not established from the material available here: Long-term safety of prasterone in women with a personal history of estrogen receptor-positive breast cancer, and any claim about relative effectiveness of prasterone versus low-dose vaginal estradiol beyond what each drug's own trial program measured.

Anyone with new pelvic pain, unexplained bleeding, or symptoms that do not improve after a full treatment trial should be evaluated by a clinician rather than adjusting a hormone regimen independently.

References

1. Urinary manifestations of genitourinary syndrome of menopause: a review of the pathophysiology, clinical presentation, and management (2026). https://pubmed.ncbi.nlm.nih.gov/42428460/
2. North American Menopause Society. The 2023 Menopause Hormone Therapy Position Statement of the North American Menopause Society. Full statement should be consulted directly for exact recommendation language: https://www.menopause.org/
3. U.S. Food and Drug Administration. Drug label and approval information for prasterone (Intrarosa) should be verified directly at the time of prescribing via the FDA's Drugs@FDA database.

Reported figures vary between studies and have not been independently confirmed here; readers should consult the original trial publications and current prescribing information for precise statistics.